News
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy
ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen® target encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT® platform and represents a new class of highly tumor‑specific targets derived from the dark proteome.
Enara Bio enters 2026 with Dark Antigen® target licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigen® targets and the development of bispecific T-cell engagers for solid tumors, today announced that Boehringer Ingelheim has exercised its option to license multiple additional Dark Antigen® targets discovered and validated through the collaboration with Enara
All News
Browse our full news archives
Upcoming & Recent Events
Discover the events that the Enara Bio team are attending